Table 2 Pharmacokinetics of clindamycin analysed by model-independent and model-dependent approach in patients with sensitive responses in Group-I and II.
Pharmacokinetic Parameters | Model-independent | Model-dependent | ||
|---|---|---|---|---|
Group-I (n = 23) | Group-II (n = 45) | Group-I (n = 23) | Group-II (n = 45) | |
tmax (hr) | 2.0 (1.0–4.0) | 3.0 (1.0–4.0) | 2.0 (0.7–3.0) | 2.4 (0.6–4.4) |
tlag (hr) | NA | NA | 0.44 (0.00–0.90) | 0.67 (0.001–1.45) |
K01 (/hr) | NA | NA | 0.62 (0.40–4.00) | 1.48 (0.11–4.00) |
t1/2a (hr) | NA | NA | 1.1 (0.1–1.7) | 0.4 (0.1–6.0) |
Cmax (μg/ml) | 4.34 (0.89–8.23)a | 6.23 (3.23–25.11) | 3.70 (1.15–5.61)b | 5.79 (3.38–18.11) |
AUC (μg.hr/ml) | 16.82 (4.07–31.46)c | 39.77 (3.41–136.16) | 21.13 (8.91–37.40)d | 52.91 (28.81–126.73) |
K10 (/hr) | NA | NA | 0.40 (0.15–0.78) | 0.18 (0.09–0.68) |
t1/2z (hr) | 2.7 (0.7–7.7)e | 4.4 (1.8–11.5) | NA | NA |
t1/2e (hr) | NA | NA | 1.0 (0.8–4.7)f | 3.9 (1.0–7.7) |
CL/F (l/hr) | 11.81 (4.70–68.56) | 11.00 (2.11–332.66) | 14.19 (8.02–33.68) | 11.85 (4.73–42.31) |
Vz/F (l) | 51.99 (11.45–207.07)g | 72.82 (24.94–896.94) | NA | NA |
V/F (l) | NA | NA | 38.12 (26.37–229.06)h | 78.85 (17.85–178.04) |
Cmin-ss (μg/ml) | 1.99 (0.87–4.56) | 1.54 (0.23–6.98) | 2.24 (0.97–24.00) | 1.66 (0.19–4.93) |
Cmax-ss (μg/ml) | 4.34 (2.10–14.00)i | 7.23 (3.45–16.54) | 4.80 (1.00–8.47)j | 6.80 (4.10–17.77) |
Cave-ss (μg/ml) | 2.80 (0.68–5.24) | 3.31 (0.28–11.35) | 1.88 (0.74–5.09)k | 4.41 (2.40–10.56) |
Cmax-min-ss (μg/ml) | 2.39 (0.22–9.88)l | 5.78 (1.89–13.33) | 2.70 (0.86–4.13)m | 4.96 (2.46–14.80) |
Fluctuation (%) | 104.4 (5.3–188.4)n | 126.2 (29.2–145.6) | 98.7 (12.9–201.2)° | 158.4 (35.7–159.2) |